HIV / AIDS
IAS 2017: PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 17 August 2017 00:00
An estimated 120,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Trans Women Wary of Antiretroviral Drug and Hormone Interactions
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
Transgender women with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminizing hormones, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: People with HIV Are at Risk for Liver Fibrosis and Steatosis
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
Metabolic syndrome, type 2 diabetes, and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do not have viral hepatitis coinfection, according to research presentedat the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil fumarate (TDF), especially if combined with ritonavir, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Medical Male Circumcision for HIV Prevention Has Benefits for Women Too
- Details
- Category: Circumcision
- Published on Thursday, 17 August 2017 00:00
South African women whose most recent sexual partner was circumcised are less likely to have HIV, suggesting that voluntary medical male circumcision programs have benefits for women, too, according to a study presented to the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: VRC01 Antibody Can Delay But Not Prevent HIV Rebound
- Details
- Category: Search for a Cure
- Published on Wednesday, 09 August 2017 00:00
A broadly neutralizing antibody modestly delayed the resurgence of viral replication following interruption of antiviral therapy (ART) started during very early infection, but all study participants ultimately experienced viral rebound, according to results presented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
More Articles...
- IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
- IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
- IAS 2017: First Protease Inhibitor Combo Pill Maintains Viral Suppression
- IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year
- IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease
Web Design and Development by